202 related articles for article (PubMed ID: 23861641)
1. Dalfampridine: review of its efficacy in improving gait in patients with multiple sclerosis.
Sahraian MA; Maghzi AH; Etemadifar M; Minagar A
J Cent Nerv Syst Dis; 2011; 3():87-93. PubMed ID: 23861641
[TBL] [Abstract][Full Text] [Related]
2. Dalfampridine: a brief review of its mechanism of action and efficacy as a treatment to improve walking in patients with multiple sclerosis.
Dunn J; Blight A
Curr Med Res Opin; 2011 Jul; 27(7):1415-23. PubMed ID: 21595605
[TBL] [Abstract][Full Text] [Related]
3. Impact of extended-release dalfampridine on walking ability in patients with multiple sclerosis.
Hayes KC
Neuropsychiatr Dis Treat; 2011; 7():229-39. PubMed ID: 21573085
[TBL] [Abstract][Full Text] [Related]
4. Treatment of walking impairment in multiple sclerosis with dalfampridine.
Blight AR
Ther Adv Neurol Disord; 2011 Mar; 4(2):99-109. PubMed ID: 21694807
[TBL] [Abstract][Full Text] [Related]
5. Clinical overview of dalfampridine: an agent with a novel mechanism of action to help with gait disturbances.
Egeberg MD; Oh CY; Bainbridge JL
Clin Ther; 2012 Nov; 34(11):2185-94. PubMed ID: 23123001
[TBL] [Abstract][Full Text] [Related]
6. Positive neurologic phenomena with initiation of dalfampridine for multiple sclerosis.
Thaera GM; Wingerchuk DM; Carter JL
Mult Scler Relat Disord; 2014 Jan; 3(1):107-9. PubMed ID: 25877980
[TBL] [Abstract][Full Text] [Related]
7. Dalfampridine in multiple sclerosis: from symptomatic treatment to immunomodulation.
Espejo C; Montalban X
Clin Immunol; 2012 Jan; 142(1):84-92. PubMed ID: 21742559
[TBL] [Abstract][Full Text] [Related]
8. Dalfampridine: a new agent for symptomatic management of multiple sclerosis.
McDonald S; Clements JN
Am J Health Syst Pharm; 2011 Dec; 68(24):2335-40. PubMed ID: 22135060
[TBL] [Abstract][Full Text] [Related]
9. Development of dalfampridine, a novel pharmacologic approach for treating walking impairment in multiple sclerosis.
Blight AR; Henney HR; Cohen R
Ann N Y Acad Sci; 2014 Nov; 1329():33-44. PubMed ID: 25154911
[TBL] [Abstract][Full Text] [Related]
10. Sustained-release fampridine for multiple sclerosis.
Bever CT; Judge SI
Expert Opin Investig Drugs; 2009 Jul; 18(7):1013-24. PubMed ID: 19548855
[TBL] [Abstract][Full Text] [Related]
11. Potassium channel blocker, 4-aminopyridine-3-methanol, restores axonal conduction in spinal cord of an animal model of multiple sclerosis.
Leung G; Sun W; Brookes S; Smith D; Shi R
Exp Neurol; 2011 Jan; 227(1):232-5. PubMed ID: 21093437
[TBL] [Abstract][Full Text] [Related]
12. Evaluating dalfampridine for the treatment of relapsing-remitting multiple sclerosis: does it add to the treatment armamentarium?
Foschi M; Lugaresi A
Expert Opin Pharmacother; 2019 Aug; 20(11):1309-1320. PubMed ID: 31237780
[No Abstract] [Full Text] [Related]
13. Pharmacology and clinical efficacy of dalfampridine for treating multiple sclerosis.
Lugaresi A
Expert Opin Drug Metab Toxicol; 2015 Feb; 11(2):295-306. PubMed ID: 25510833
[TBL] [Abstract][Full Text] [Related]
14. The safety profile of dalfampridine extended release in multiple sclerosis clinical trials.
Cornblath DR; Bienen EJ; Blight AR
Clin Ther; 2012 May; 34(5):1056-69. PubMed ID: 22497693
[TBL] [Abstract][Full Text] [Related]
15. Extended-release dalfampridine in the management of multiple-sclerosis-related walking impairment.
Hersh C; Rae-Grant A
Ther Adv Neurol Disord; 2012 Jul; 5(4):199-204. PubMed ID: 22783369
[TBL] [Abstract][Full Text] [Related]
16. Sustained-release fampridine for symptomatic treatment of multiple sclerosis.
Korenke AR; Rivey MP; Allington DR
Ann Pharmacother; 2008 Oct; 42(10):1458-65. PubMed ID: 18780812
[TBL] [Abstract][Full Text] [Related]
17. Real-life experience with fampridine (Fampyra®) for patients with multiple sclerosis and gait disorders.
Fragoso YD; Adoni T; Alves-Leon SV; Apostolos-Pereira SL; Barreira AA; Brooks JB; Claudino R; Correa EC; Ferreira ML; Finkelsztejn A; Finkelsztejn J; da Gama PD; Goncalves MV; Guerreiro CT; da Cunha Matta AP; Marques VD; Rizo Morales R; Parolin MF; de Castro Ribeiro M; Ribeiro TA; Ruocco HH; Sato H; Scherpenhuijzen S; Siquineli F; de Carvalho Sousa NA; Varela DL; Tauil CB; Winckler TC
NeuroRehabilitation; 2016 Jun; 39(2):301-4. PubMed ID: 27372365
[TBL] [Abstract][Full Text] [Related]
18. Early effect of dalfampridine in patients with MS: A multi-instrumental approach to better investigate responsiveness.
Brambilla L; Rossi Sebastiano D; Aquino D; Torri Clerici V; Brenna G; Moscatelli M; Frangiamore R; Giovannetti AM; Antozzi C; Mantegazza R; Franceschetti S; Bruzzone MG; Erbetta A; Confalonieri P
J Neurol Sci; 2016 Sep; 368():402-7. PubMed ID: 27538672
[TBL] [Abstract][Full Text] [Related]
19. Chronic Demyelination and Axonal Degeneration in Multiple Sclerosis: Pathogenesis and Therapeutic Implications.
Simkins TJ; Duncan GJ; Bourdette D
Curr Neurol Neurosci Rep; 2021 Apr; 21(6):26. PubMed ID: 33835275
[TBL] [Abstract][Full Text] [Related]
20. Dalfampridine in multiple sclerosis.
Goodman AD; Hyland M
Drugs Today (Barc); 2010 Sep; 46(9):635-9. PubMed ID: 20967295
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
